Breaking News Instant updates and real-time market news.

2016-10-19 07:39:52

MRNS

Marinus Pharmaceuticals

$1.39

0.02 (1.46%)

07:39

10/19/16

10/19

07:39

10/19/16

07:39

Marinus says ganaxolone Phase 1 data supports progressing to Phase 2

Marinus Pharmaceuticals announced that in its Phase 1 dose-escalation study, ganaxolone intravenous achieved dose levels targeted for efficacy in patients with status epilepticus and other indications. Status epilepticus is a life-threatening medical emergency associated with high mortality and limited treatments. Typically, single or combination IV antiepileptic drugs are used in an attempt to break the seizures, however there are approximately 45,000 patients in the U.S. who do not respond to first-line treatment.

MRNSMarinus Pharmaceuticals

$1.39

0.02 (1.46%)

09/30/16

JMPS

09/30/16NO CHANGEJMPS

Marinus Pharmaceuticals data positive, says JMP Securities

JMP Securities analyst Jason Butler says that a trial of Marinus' ganaxolone PCDH19 in female pediatric eplilepsy yielded "promising" results. The analyst says that the data is positive, while female pediatric eplilepsy is an unmet need. Butler keeps a $5 price target and Outperform rating on the shares.

06/20/16

LEER

06/20/16NO CHANGETarget $66LEEROutperform

Leerink remains positive on SAGE Therapeutics ahead of data catalysts

After meeting with SAGE Therapeutics' (SAGE) CEO Jeff Jonas and CFO Kimi Iguchi, Leerink analyst Paul Matteis says he continues to see a positive risk and reward for the company's stock ahead of multiple near-term data catalysts. Additionally, the analyst says he views the recent failure of Marinus Pharmaceuticals' (MRNS) ganaxolone in focal onset seizures as likely due to a bioavailability issue, not a mechanistic deficiency, and thus shouldn't read negatively on the potential of SAGE Therapeutics' SAGE-217. Matteis reiterates an Outperform rating and $66 price target on SAGE's shares.

RBC Capital downgraded Marinus after the company announced that its first Phase 3 epilepsy study for adult focal onset seizures failed to meet its primary endpoint. Target to $2 from $14.

06/14/16

JEFF

06/14/16NO CHANGETarget $2.5JEFFBuy

Marinus price target lowered to $2.50 from $13 at Jefferies

Jefferies analyst Brian Abrahams cut his price target for Marinus Pharmaceuticals to $2.50 from $13 after ganaxolone failed in a late-stage seizure study. The analyst, however, still sees residual value for the company given ganaxolone evidence of activity and consistent on-target safety profile. He thinks shares could rebound to $2.50 and keeps a Buy rating on Marinus.